WALDENSTRÖM'S MACROGLOBULINEMIA

Waldenström's macroglobulinemia is a chronic lymphoproliferative disorder characterized by a clonal proliferation of B lymphocytes or lymphoplasmacytic cells in bone marrow or in lymph nodes, or both, and a high concentration of monoclonal IgM M‐protein, typically exceeding 3 g/dL.

Immunophenotypping:

 

Positive for pan-B markers (CD19, CD20, CD22, CD24) together with cytoplasmic immunoglobulin (IgM, IgD), FMC-7, CD25, predominantly kappa (5:1, kappa:lambda ratio),variable CD20, CD22, CD38, variable CD43, CD138  and Negative for CD5 (usually), CD10, CD11c, CD23, BCL2, CD103

References

  • Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 4th ed Lyon, France: IARC Press; 2008.

  • Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824–833. pmid:20702770. View Article

  • Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110–115. pmid:12720118. View Article

  • Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma. 2012;53(8):1625–1626. pmid:22239669. View Article

  • Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer. 1998;82(6):1078–1081. pmid:9506352. View Article

  • Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–420. pmid:16191510. View Article

  • Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–607. pmid:22460905. View Article

  • Barakat FH, Medeiros LJ, Wei EX, Konoplev S, Lin P, Jorgensen JL. Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. Am J Clin Pathol. 2011;135(3):365–373. pmid:21350089. View Article

  • Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenstrom's macroglobulinemia. Mod Pathol. 2009;22(6):807–816. pmid:19287458. View Article

  • Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, et al. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute—Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013;54(2):387–396. pmid:22812491. View Article

Scholar Google Plagiarism Software

       Article invited for

          Vol 5,Issue 3,

                  2020

flowcytometry events

Copyright © 2015  www.flowcytometrynet.com. All right reserved
Follow Us
  • Facebook Basic Square
  • Google+ Basic Square